摘要
目的：观察尼妥株单抗联合化疗治疗晚期胃癌的疗效及毒副反应.方法：采用尼妥株单抗联合传统化疗药物治疗13例晚期胃癌患者,尼妥株单抗首剂负荷量400mg/m2,之后每周给予维持剂量250mg/m2,并联合常用化疗方案,化疗2～3个周期后评价疗效.结果：13例患者中,一线治疗6例,获PR 2例,SD 4例;多线治疗7例,获PR1例,SD 2例,PD 3例,1例疗效无法评价.主要毒副反应为骨髓抑制、胃肠道反应和皮肤黏膜反应.截至2012年12月30日,13例患者中存活2例,死亡11例,生存时间为3.9～40.8个月,中位生存时间（OS）为16.4个月（95％CI：8.4～20.4个月）.结论：尼妥株单抗联合化疗治疗国人晚期胃癌可能有较好的疗效与安全性,但需要扩大样本进一步研究.
Objective ：To investigate the efficacy and side effects of Nimotuzumab plus chemotherapy in treatment of advanced gastric cancer. Methods：Thirteen patients with advanced gastric cancer were treated with Nimotuzumab plus traditional chemotherapy, Nimotuzumab 400m/ m^2 was taken at the first dose and a maintenance dose was 250m/m^2 every week. The curative effects were evaluated after2-3 cycles. Results： Out of the total 13 patients, 6 cases received first-line treatment, 2 with PR, 4 with SD;seven cases received multi-chemotherapy treat- ment, 1 with PR, 2 with SD, 3 with PD, and 1 case could not be evaluated. The main toxic reactions were myelosuppression, digestive tract reaction and skin anrl mucosa reactions. Until the deadline date （December30,2012）, two of the 13 patients survived, and 11 patients died. The survival time ranged from 3.9 to 40.8 months, and the median survival time was 16.4 months （95% CI： 8.4-20.4）. Conclusion ：Nimotuzumab plus chemotherapy in the treatment of advanced gastric cancer may have good efficacy and toxicity can be tolerated.
出处
《内蒙古中医药》
2014年第5期6-7,共2页
Inner Mongolia Journal of Traditional Chinese Medicine
关键词
胃癌
尼妥株单抗
化学治疗
Gastric cancer
Nimotuzumab
Chemotherapy
